SAM
LAB icon

Shell Asset Management’s Standard BioTools LAB Stock Holding History

Shell Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$17K Buy
13,346
+1,083
+9% +$1.42K ﹤0.01% 1056
2025
Q2 		$15K Hold
12,263
– – ﹤0.01% 1239
2025
Q1 		$13K Sell
12,263
-500
-4% -$702 ﹤0.01% 1242
2024
Q4 		$22K Hold
12,763
– – ﹤0.01% 1240
2024
Q3 		$25K Buy
+12,763
New +$25K ﹤0.01% 1230
2024
Q1 		$24K Buy
+13,548
New +$32.7K ﹤0.01% 1223

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Shell Asset Management's LAB Position: Q3 2025 in Review

Shell Asset Management increased its Standard BioTools (LAB) stake by 8.8% in Q3 2025, buying an estimated $1.42K and bringing the position to 13,346 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1056.

Shell Asset Management first reported a position in LAB in Q1 2024 and has held it in 6 quarters since. The position peaked at $25K in Q3 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q3 2025.

  • Shell Asset Management held 13,346 shares of Standard BioTools worth $17K as of Q3 2025.
  • Shell Asset Management bought 1,083 Standard BioTools shares in Q3 2025, an estimated $1.42K.
  • Standard BioTools made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #1056 holding.
  • Shell Asset Management first reported a position in Standard BioTools in Q1 2024 and has held it in 6 quarters since.
  • Shell Asset Management's Standard BioTools position peaked at $25K in Q3 2024.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.